Advanced Search Results For "AND COVID-19 Subject OR COVID-19 pandemic Subject OR SARS-CoV-2 Subject OR SARS-CoV-2 Delta variant Subject OR SARS-CoV-2 Omicron variant Subject "
Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 – February 2022).
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases. Apr2023, Vol. 129, p135-141. 7p.
Abstract: • We estimated the impact of Omicron vs Delta variant on severe COVID-19 in Italy. • The Omicron variant had a reduced risk compared to the Delta variant (incidence rate ratio = 0.77). • The largest difference was observed in cases aged 40-59 years (in...
Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic.
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases. Jul2023, Vol. 132, p72-79. 8p.
Abstract: • SARS-CoV-2 reinfection incidence was 2.7% versus 21.6% for Delta versus Omicron variants. • COVID-19 vaccination reduced the reinfection risk with the Delta and Omicron variants. • A high antinucleocapsid level during the first illness markedly reduc...
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases. Apr2023, Vol. 129, p19-31. 13p.
Abstract: • No safety concern of the third dose boosting with either vaccine. • Half-dose immunogenicity of either vaccine was noninferior to the full dose. • Both doses elicited high immunogenicity and were best with longer boost intervals. • The immunogenicity...
Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 – February 2022)
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases, Vol 129, Iss , Pp 135-141 (2023)
Abstract: Objectives: During 2022, Omicron became the dominant SARS-CoV-2 variant in Europe. This study aims to assess the impact of such variant on severe disease from SARS-CoV-2 compared with the Delta variant in Italy. Methods: Using surveillance data, we ass...
Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy.
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases. Sep2022, Vol. 122, p420-426. 7p.
Abstract: • Fragile individuals appear to be more susceptible to lower vaccine effectiveness. • The Omicron variant seems to cause less severe COVID-19. • During the Delta wave, a higher number of nonvaccinated individuals were admitted to the intensive care uni...
Worldwide vaccine inequality threatens to unleash the next COVID-19 variant.
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases. Oct2022, Vol. 123, p133-135. 3p.
Abstract: • Significant inequities remain in COVID-19 vaccine distribution and vaccination rates worldwide. • Worldwide COVID-19 vaccine distribution is complicated by supply, logistics, and vaccine hesitancy. • Recent COVID-19 variants have emerged from regions...
Simultaneous co-infection with Omicron (B.1.1.529) and Delta (21A/478K.V1) SARS-CoV-2 variants confirmed by whole genome sequencing
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases, Vol 124, Iss , Pp 104-106 (2022)
Abstract: We reported herein a simultaneous co-identification with Omicron (B.1.1.529) and Delta (21A/478K.V1) SARS-CoV-2 variants, confirmed by whole genome sequencing in an 83-year-old French patient.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases. Jan2023, Vol. 126, p164-173. 10p.
Abstract: • FINLAY-FR-2 conjugate vaccine is safe and immunogenic in children 3-18 years old. • The third dose with FINLAY-FR-1A (dimer receptor binding domain vaccine) increases the immune response. • The heterologous three-dose schedule elicited specific T-cel...
Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases, Vol 122, Iss , Pp 420-426 (2022)
Abstract: Objective: We compared the characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized with COVID-19. Design: We analyzed patients hospitalized in a COVID hub during three one-month periods: (i) October 15, 2020-November 15, 2020...
Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract: a systematic review and meta-analysis.
Publication Type: Academic Journal
Source(s): International Journal of Infectious Diseases. Apr2023, Vol. 129, p228-235. 8p.
Abstract: • The duration of viable virus shedding of the Omicron variant was 5.16 days. • The average duration of polymerase chain reaction positivity of the Omicron variant was 10.82 days. • The duration in symptomatic patients was higher than that in asymptoma...